Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 15/20 | 0.50 |
| ▸ | CTSL | P07711 | 10/20 | 0.50 |
| ▸ | CTSK | P43235 | 6/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841162 | 0.91 | CTSS (0.53) | CTSSCTSLCTSKUSP30 | |
| SCHEMBL5842862 | 0.90 | CTSS (0.52) | CTSSCTSLCTSKUSP30 | |
| SCHEMBL5842009 | 0.87 | CTSS (0.57) | CTSSCTSLCTSKEPHX2TAS1R3 | |
| SCHEMBL5844353 | 0.86 | CTSS (0.55) | CTSSCTSLCTSKUSP30 | |
| SCHEMBL5841716 | 0.86 | CTSS (0.46) | CTSSCTSLCTSKUSP30SLC6A9 | |
| SCHEMBL5842618 | 0.86 | CTSS (0.48) | CTSSCTSLCTSKUSP30EPHX2 | |
| SCHEMBL5842678 | 0.85 | CTSS (0.51) | CTSSCTSLCTSKEPHX2 | |
| SCHEMBL5842643 | 0.84 | GRN (0.55) | CTSSCTSLCTSKEPHX2 | |
| SCHEMBL5843557 | 0.84 | CTSS (0.48) | CTSSCTSLCTSKUSP30EPHX2 | |
| SCHEMBL5844306 | 0.84 | CTSS (0.45) | CTSSCTSLCTSKUSP30TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | claimed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198780-A1 | Inhibitors of cathepsin S | CTSS, CTSK, CTSE | CTSS 1/4885CTSL 10/4885CTSK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.